Karuna's schiz­o­phre­nia drug pass­es a close­ly-watched PhI­II test, will head to FDA in mid-2023

An in­ves­ti­ga­tion­al pill that com­bines a for­mer Eli Lil­ly CNS com­pound with an over­ac­tive blad­der drug was bet­ter than place­bo at re­duc­ing a scale of symp­toms ex­pe­ri­enced by pa­tients with schiz­o­phre­nia in a Phase III tri­al.

Karuna Ther­a­peu­tics’ drug passed the pri­ma­ry goal in EMER­GENT-2, the Boston biotech said ear­ly Mon­day morn­ing, along­side quar­ter­ly earn­ings. The study is the first of Karuna’s four Phase III clin­i­cal tri­als to read out in schiz­o­phre­nia and will pro­vide the back­bone to the biotech’s first drug ap­proval ap­pli­ca­tion, slat­ed for mid-2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER